Comparison · NCT03237065-b6514157
Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL). Trial comparisons, record NCT03237065-b6514157. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03237065-b6514157
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0806 | 0.0349 | 0.175 | wilson | |
| Risk in group 2 | 0.737 | 0.61 | 0.834 | wilson | |
| Risk difference, group 1 minus group 2 | -0.656 | -0.763 | -0.498 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.109 | 0.0466 | 0.257 | log | |
| Odds ratio, group 1 over group 2 | 0.0313 | 0.0106 | 0.093 | log | |
| Number needed to treat, for one fewer participant with the outcome on Iron Isomaltoside/Ferric Derisomaltose than on Ferric Carboxymaltose | 1.52 | 1.31 | 2.01 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | 5 | 62 | OG000 |
| Group 2 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV | 42 | 57 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL)
- Description
- Safety~The incidence of hypophosphatemia (defined as s-phosphate \<2 mg/dL) at any time from baseline up to day 35.
- Time frame
- Baseline to day 35
- Population
- Safety analysis set: included all subjects who received at least one dose of the investigational product.
Source ClinicalTrials.gov
Trial
- Title
- Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
- NCT number
- NCT03237065
- Phases
- PHASE3
- Conditions
- Iron Deficiency Anaemia, Iron Deficiency Anemia
- Interventions
- Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose
- Lead sponsor
- Pharmacosmos A/S
- Results first posted
- 2020-02-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03237065?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03237065-b6514157